Eyepoint Net Income From Continuing Ops from 2010 to 2026
| EYPT Stock | USD 14.70 0.34 2.37% |
Net Loss | First Reported 2003-06-30 | Previous Quarter -59.4 M | Current Value -59.7 M | Quarterly Volatility 13.9 M |
Check Eyepoint Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyepoint Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 15.3 K or Total Revenue of 52.3 M, as well as many indicators such as Price To Sales Ratio of 10.59, Dividend Yield of 0.0 or PTB Ratio of 1.36. Eyepoint financial statements analysis is a perfect complement when working with Eyepoint Pharmaceuticals Valuation or Volatility modules.
Eyepoint | Net Income From Continuing Ops | Build AI portfolio with Eyepoint Stock |
The evolution of Net Income From Continuing Ops for Eyepoint Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Eyepoint Pharmaceuticals compares to historical norms and industry peers.
Latest Eyepoint Pharmaceuticals' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Eyepoint Pharmaceuticals over the last few years. It is Eyepoint Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eyepoint Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Eyepoint Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (55,418,050) | |
| Geometric Mean | 40,513,233 | |
| Coefficient Of Variation | (75.65) | |
| Mean Deviation | 34,304,406 | |
| Median | (53,171,000) | |
| Standard Deviation | 41,923,544 | |
| Sample Variance | 1757.6T | |
| Range | 137.2M | |
| R-Value | (0.87) | |
| Mean Square Error | 452.2T | |
| R-Squared | 0.76 | |
| Slope | (7,231,816) | |
| Total Sum of Squares | 28121.3T |
Eyepoint Net Income From Continuing Ops History
About Eyepoint Pharmaceuticals Financial Statements
Eyepoint Pharmaceuticals shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Eyepoint Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Eyepoint Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Eyepoint Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -117.8 M | -111.9 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.